PMID- 33471718
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20231110
IS  - 1530-891X (Print)
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 26
IP  - 10
DP  - 2020 Oct
TI  - Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in 
      Covid-19.
PG  - 1166-1172
LID - S1530-891X(20)48222-9 [pii]
LID - 10.4158/EP-2020-0466 [doi]
AB  - OBJECTIVE: Although type 2 diabetes mellitus (T2DM) has been reported as a risk 
      factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic 
      agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains 
      unclear. Metformin increases the expression of angiotensin converting enzyme 2, a 
      known receptor for severe acute respiratory syndrome coronavirus 2. Data from 
      people with T2DM hospitalized for COVID-19 were used to test the hypothesis that 
      metformin use is associated with improved survival in this population. METHODS: 
      Retrospective analyses were performed on de-identified clinical data from a major 
      hospital in Wuhan, China, that included patients with T2DM hospitalized for 
      COVID-19 during the recent epidemic. One hundred and thirty-one patients 
      diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was 
      mortality. Demographic, clinical characteristics, laboratory data, diabetes 
      medications, and respiratory therapy data were also included in the analysis. 
      RESULTS: Of these 131 patients, 37 used metformin with or without other 
      antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) 
      survived and 2 (5.4%) did not survive. The mortality rates in the 
      metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 
      22.3% (21/94). Using multivariate analysis, metformin was found to be an 
      independent predictor of survival in this cohort (P = .02). CONCLUSION: This 
      study reveals a significant association between metformin use and survival in 
      people with T2DM diagnosed with COVID-19. These clinical data are consistent with 
      potential benefits of the use of metformin for COVID-19 patients with T2DM.
CI  - (c) 2020 American Association of Clinical Endocrinologists. Published by Elsevier, 
      Inc. All rights reserved.
FAU - Li, Jinghong
AU  - Li J
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Wei, Qi
AU  - Wei Q
AD  - the Department of Endocrinology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
FAU - Li, Willis X
AU  - Li WX
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - McCowen, Karen C
AU  - McCowen KC
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Xiong, Wei
AU  - Xiong W
AD  - the Department of Endocrinology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
FAU - Liu, Jiao
AU  - Liu J
AD  - the Department of Endocrinology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
FAU - Jiang, Wenlijun
AU  - Jiang W
AD  - the Department of Endocrinology, Wuhan Red Cross Hospital, Wuhan, Hubei, China.
FAU - Marin, Traci
AU  - Marin T
AD  - the Department of Health Sciences, Victor Valley College, Victorville, 
      California.
FAU - Thomas, Robert L
AU  - Thomas RL
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - He, Ming
AU  - He M
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Gongol, Brendan
AU  - Gongol B
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Hepokoski, Mark
AU  - Hepokoski M
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Yuan, Jason X-J
AU  - Yuan JX
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
FAU - Shyy, John Y-J
AU  - Shyy JY
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California. Electronic address: jshyy@health.ucsd.edu.
FAU - Xiong, Nian
AU  - Xiong N
AD  - the Department of Endocrinology, Wuhan Red Cross Hospital, Wuhan, Hubei, China; 
      the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.. Electronic address: 
      nianxiong@hust.edu.cn.
FAU - Malhotra, Atul
AU  - Malhotra A
AD  - From the Department of Medicine, University of California, San Diego, La Jolla, 
      California.
LA  - eng
GR  - R01 HL108735/HL/NHLBI NIH HHS/United States
GR  - T32 HL134632/HL/NHLBI NIH HHS/United States
GR  - K24 HL132105/HL/NHLBI NIH HHS/United States
GR  - R01 HL090897/HL/NHLBI NIH HHS/United States
GR  - R01 HL085188/HL/NHLBI NIH HHS/United States
GR  - R01 HL140898/HL/NHLBI NIH HHS/United States
GR  - R01 AG063925/AG/NIA NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *COVID-19
MH  - China
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Hospitalization
MH  - Humans
MH  - *Metformin/therapeutic use
MH  - Retrospective Studies
MH  - SARS-CoV-2
PMC - PMC7834011
MID - NIHMS1666355
EDAT- 2021/01/21 06:00
MHDA- 2021/01/23 06:00
PMCR- 2020/12/28
CRDT- 2021/01/20 17:09
PHST- 2020/07/11 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2021/01/20 17:09 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
PHST- 2020/12/28 00:00 [pmc-release]
AID - S1530-891X(20)48222-9 [pii]
AID - 10.4158/EP-2020-0466 [doi]
PST - ppublish
SO  - Endocr Pract. 2020 Oct;26(10):1166-1172. doi: 10.4158/EP-2020-0466.